Browsing Tag
Acute myeloid leukemia
39 posts
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven
Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based…
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth…
BioTheryX begins BTX-A51 phase 1 trial in AML and myelodysplastic syndrome
BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program…
Trovagene’s Onvansertib-decitabine combination trial shows promising results
Trovagene, a California-based cancer research company, has announced the successful completion of the second dosing cohort in its…
Cantex Pharmaceuticals’ CX-01 receives FDA fast track designation in acute myeloid leukemia
Cantex Pharmaceuticals, a Florida-based biotechnology company, has achieved a significant milestone by securing Fast Track designation from the…
Tolero Pharmaceuticals and AbbVie collaborate to advance AML treatment
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie to explore the potential of combining their…
FDA approves Agios Pharmaceuticals’ Tibsovo for targeted acute myeloid leukemia treatment
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals for Tibsovo (ivosidenib), designed for…
FDA approves Agios Pharmaceuticals’ TIBSOVO for acute myeloid leukemia
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals’ TIBSOVO (ivosidenib) for the treatment…
Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial
Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not…